Hepatitis C

With an estimate of as many as 80 million people infected with hepatitis C globally, access to treatment worldwide must be scaled up. To ensure this, the price of oral drugs to treat hepatitis C urgently needs to come down in all developing countries, particularly through competition among generic producers.

27. March 2016.

MSF joins Europe-wide action challenging patent on key hepatitis C drug

Patent opposition aims to increase affordable access to hepatitis C drug sofosbuvir for millions. Read more


Hepatitis C strategies

Hep-C patient being counselled by Psychosocial counsellor at MSF Mumbai clinic on dealing with side effects of the treatment regimen - Photo by Siddharth Singh

Strategies to Secure Access to Generic Hepatitis C Medicines

MSF is in the process of starting to treat people who are living with hepatitis C virus (HCV) in at least nine countries, and therefore is in need of affordable access to direct acting antiviral (DAA) treatments, including those marketed by Gilead Sciences (Gilead) and Bristol-Myers Squibb (BMS). Read more

Learn more

Featured multimedia

Hepatitis C: A Call to Action
In 2016, WHO estimated that the hepatitis C virus (HCV) and associated complications claim 700,000 lives...

Tags: hepatitis c, co-infection

↑ To top